A potent topical combination therapy consisting of a super-high potency corticosteroid (Clobetasol Propionate) and a bacteriostatic antibiotic (Fusidic Acid). It is primarily indicated for the treatment of inflammatory dermatoses complicated by or at high risk of secondary bacterial infections, particularly those caused by Staphylococcus aureus, including methicillin-resistant strains (MRSA). Clobetasol provides rapid and potent anti-inflammatory, anti-pruritic, and vasoconstrictive effects, while Fusidic Acid targets gram-positive bacterial pathogens. This combination is highly effective but carries significant risks of local and systemic side effects due to the potency of clobetasol, necessitating short-term, supervised use.
Adult: Apply a thin film to the affected area once or twice daily. Treatment should be limited to 2 consecutive weeks. The maximum weekly dose should not exceed 50 grams of cream/ointment.
Note: 1. Wash and dry hands and affected area. 2. Apply a thin layer and rub gently until it disappears. 3. Do not bandage, wrap, or cover the treated area unless specifically directed by a physician (occlusive dressing dramatically increases absorption and risk of side effects). 4. Avoid contact with eyes, mouth, nose, and mucous membranes. 5. Wash hands after application unless hands are the treatment area.
The combination exerts a dual mechanism: 1) Clobetasol propionate binds to intracellular glucocorticoid receptors, modulating gene transcription. This leads to the synthesis of anti-inflammatory proteins (lipocortin) and inhibition of pro-inflammatory mediators (cytokines, leukotrienes, prostaglandins). It also causes vasoconstriction. 2) Fusidic acid inhibits bacterial protein synthesis by binding to elongation factor G (EF-G), preventing translocation on the ribosome and thus inhibiting bacterial growth, specifically against gram-positive organisms.
Pregnancy: Pregnancy Category C (US FDA). Topical corticosteroids, especially potent ones, can be absorbed in amounts sufficient to cause systemic effects. Animal studies show teratogenicity. Use only if the potential benefit justifies the potential risk to the fetus. Avoid large areas, prolonged use, or occlusive dressings.
Driving: No known effects on driving ability.
| Other Topical Corticosteroids | Additive risk of local and systemic side effects, including HPA axis suppression. | Major |
| Oral Corticosteroids (e.g., Prednisolone) | Increased risk of systemic corticosteroid effects and HPA axis suppression. | Major |
| Topical Retinoids (e.g., Tretinoin) | Increased risk of severe local irritation and skin atrophy. | Moderate |
| Topical Immunosuppressants (e.g., Tacrolimus, Pimecrolimus) | Theoretical increased risk of infection and malignancy; concurrent use not recommended. | Moderate |
| CYP3A4 Inhibitors (e.g., Ketoconazole, Itraconazole, Clarithromycin) | May inhibit metabolism of systemically absorbed clobetasol, increasing systemic exposure and toxicity risk. | Moderate |
Same composition (Clobetasol (0.05% w/w) + Fusidic Acid (2% w/w)), different brands: